Prostate Cancer Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Prostate Cancer Diagnostics Market Trends and Insights

Rising Prostate Cancer Screening Volume

The prostate cancer diagnostics market is gaining from a broader rise in organized and semi-organized screening activity across several countries. Prostate cancer is now the most commonly diagnosed cancer in men in 118 of 185 countries, which supports the need for more routine testing pathways in both mature and under-screened health systems. Japan’s 2025 clinical practice guidelines introduced the first weak recommendation in favor of PSA screening for middle-aged men, which marked a clear shift from the long period of uncertain official guidance.^{[1]Japanese Urological Association, “Prostate Cancer Clinical Practice Guidelines 2025 Edition,” Minds Clinical Practice Guideline, minds.jcqhc.or.jp} In the United States, the prostate cancer death rate fell by 50% between 1993 and 2022, which keeps the case for earlier detection central to screening decisions. Lombardy’s multilevel screening pilot enrolled 8,558 men by June 2025 and recorded a 15.9% referral rate without evidence of overdiagnosis, which gives the prostate cancer diagnostics market a practical model for urban screening scale-up. Higher screening volume supports repeat demand for PSA reagents, follow-on biomarker work, imaging, and biopsy across the wider prostate cancer diagnostics market.

Expanding Reimbursement for Advanced Biomarker and Imaging Tests

The prostate cancer diagnostics market is also being lifted by coverage decisions that reduce ordering uncertainty for clinicians and laboratories. CMS updated its Local Coverage Determination for the Decipher Prostate Cancer Classifier Assay, effective July 3, 2025, and that decision covered use in localized prostate cancer patients with at least 10 years of life expectancy under NCCN-aligned criteria.^{[2]Centers for Medicare & Medicaid Services, “MolDX, Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38341),” CMS, cms.gov} Once a molecular test gains reimbursement, it becomes easier for similar tools to frame their own value in terms that payers already recognize. The same pattern matters for advanced imaging, because reimbursement changes shape referral behavior, budget planning, and vendor investment decisions across the prostate cancer diagnostics market. The direct effect is stronger in systems where coverage policy quickly translates into everyday clinical pathways, especially in the United States and other reimbursement-led markets. Over time, this creates a more stable commercial floor for the prostate cancer diagnostics market than clinical enthusiasm alone could provide.

Liquid Biopsy and Genomic Testing Uptake

The prostate cancer diagnostics market is moving toward a more longitudinal testing model, and liquid biopsy is part of that shift. ASCO guidance in 2025 supported ctDNA use when tissue is inaccessible or when serial monitoring is needed, which moved liquid biopsy further into routine metastatic care.^{[3]M. Hussain, “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer, ASCO Guideline,” Journal of Clinical Oncology, ascopubs.org} A 2026 prospective cohort study in Nature Cancer found that ctDNA positivity after 6 to 12 weeks of combination androgen deprivation therapy was independently associated with 12-month and 24-month survival outcomes in high-volume metastatic disease. That evidence matters because it gives molecular testing clinical relevance beyond a single baseline readout. It also supports repeat-testing economics for the prostate cancer diagnostics market, especially where physicians need to track response or progression without repeated tissue sampling. As these use cases expand, the prostate cancer diagnostics market gains a higher-value layer that is less exposed to standard screening price pressure.

The prostate cancer diagnostics market is also being shaped by AI systems that aim to reduce unnecessary biopsies and improve MRI interpretation consistency. A multicenter UK study published in European Radiology in 2026 validated an AI decision-support tool that combined PI-RADS scores, automated PSA density, and deep learning imaging risk scores across 6 centers. A 2025 Nature Communications study reported prospective clinical use of ProAI, a fully automated deep learning system that improved diagnostic performance and workflow efficiency in real hospital settings. A 2026 study in npj Digital Medicine reported that Prost-LM achieved an internal validation AUC of 0.954 for prostate cancer versus benign conditions across a 3,940-patient multicenter cohort, compared with 0.868 for MRI-only models. These results favor companies that can pair algorithm development with prospective validation and regulatory discipline. That dynamic can widen the role of the prostate cancer diagnostics market in radiology and urology workflows without displacing the underlying need for pathology confirmation.

High Out-of-Pocket Cost for Advanced Diagnostics

The prostate cancer diagnostics market still faces a clear affordability barrier in advanced testing categories. ASCO’s 2025 guideline noted that ctDNA liquid biopsy tests are priced at USD 1,000 to USD 3,000 per test, and genomic classifiers often fall into a similar range. Those price levels can suppress both physician ordering and patient uptake outside strong reimbursement frameworks. Access differences are not only financial, because a 2025 Medicare claims study in Cancer Imaging found materially lower PSMA PET use among rural patients and the sharpest gap among Black patients in rural settings. This means advanced testing volume remains concentrated in insured, urban, and academically linked populations. That concentration limits how fully the prostate cancer diagnostics market can reflect the true epidemiological burden of disease across broader populations.

Variable Clinical Utility and PSA Overdiagnosis Concerns

The prostate cancer diagnostics market also remains constrained by the long-standing limits of PSA-led screening. PSA can generate false positives and can identify indolent cancers that do not require intervention, which keeps the screening policy cautious in several major systems. The U.S. Preventive Services Task Force's position on shared decision-making for men aged 55 to 69 and its recommendation against systematic screening at older ages continue to set practical limits on broad screening expansion. Japan still shows mixed signals because the Ministry of Health position remained cautious while the Japanese Urological Association’s 2025 guidance moved toward weak support for individual testing. A 2026 review in Cancers found that ctDNA was detectable in only 43% of localized prostate cancer cases with PSA below 10 ng/mL, which means molecular escalation is not always productive in low-risk settings. That slows adoption of more expensive multimodal protocols in health systems that still need clearer proof of incremental value above PSA alone.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Diagnostic Technology: PSMA PET Converts Niche Adoption Into Clinical Standard

PSA and biomarker testing held 46.31% of the prostate cancer diagnostics market share in 2025, while PSMA PET and CT imaging is projected to grow at an 8.68% CAGR through 2031. PSA-based testing remains the broad volume base of the prostate cancer diagnostics market because it is scalable, low-cost, and widely embedded in primary care and referral pathways. PSMA PET has moved into a different position because its role is now tied more closely to staging quality and downstream treatment selection. Journal of Nuclear Medicine data showed that PSMA PET use among high-risk and very-high-risk patients in the VA system had risen to 70% by mid-2023 after guideline support strengthened. MRI and mpMRI continue to gain value as pre-biopsy triage tools, especially in health systems that want to reduce unnecessary biopsy volume while preserving detection of clinically significant disease.

Biopsy and histopathology still remain central to definitive diagnosis, grading, and subtype assessment across the prostate cancer diagnostics market. The more important change is that imaging now has stronger clinical authority before biopsy and around therapy decisions, rather than only after pathology. PSMA PET carries added relevance because it links diagnosis with theranostic pathways, which raises its importance beyond a single imaging event. This makes the prostate cancer diagnostics industry more dependent on vendors that can align clinical evidence, tracer supply, reimbursement, and physician education at the same time. At the same time, PSA and related biomarker tests are likely to remain the largest technology category because no other platform matches their population-level reach and repeat-testing frequency.

By Sample Type: Tissue Reclaims Diagnostic Relevance in the Precision Therapy Era

Blood-based samples represented 46.68% of the prostate cancer diagnostics market size in 2025, while tissue is the fastest-growing sample type with a 10.12% CAGR through 2031. Blood remains dominant because PSA testing still drives the highest routine volume in the prostate cancer diagnostics market, and ctDNA has widened the role of blood in advanced disease management. Tissue is growing faster because treatment selection increasingly depends on immunohistochemistry and genomic profiling that cannot always be replaced by liquid biopsy. This shifts tissue from a traditional confirmation role toward a recurring precision-oncology role in selected patients. Urine-based diagnostics are also drawing interest at the decentralized end of the pathway because they can fit low-friction collection models and may help refine pre-biopsy risk selection.

The sample mix now reflects a more layered clinical pathway inside the prostate cancer diagnostics market rather than a single dominant specimen logic. Blood remains the main entry point for screening and routine monitoring. Tissue becomes more important when physicians need deeper characterization for therapy planning or for higher-confidence disease classification. Urine fits best where providers want a noninvasive step between PSA signal and invasive workup, while saliva and other biospecimens remain early-stage options with limited routine use. This mix favors companies that can operate across more than one sample type and support both broad-volume testing and high-specificity downstream decisions in the prostate cancer diagnostics industry.

By Cancer Type: Rare Subtypes Drive Molecular Platform Investment

Prostatic adenocarcinoma accounted for 88.16% of the cancer type segment in 2025, making it the clear commercial core of the prostate cancer diagnostics market. Small cell carcinoma of the prostate is projected to expand at a 9.34% CAGR through 2031, even though it remains much smaller in absolute volume. The faster growth reflects rising recognition of treatment-emergent neuroendocrine differentiation in castration-resistant settings and the diagnostic difficulty created by PSA-silent biology. A 2026 study in npj Precision Oncology showed that aggressive variant prostate cancer, including small cell and neuroendocrine forms, requires integrative molecular characterization that goes well beyond standard PSA measures. That creates a commercial case for next-generation sequencing and multi-omic platforms even when the underlying subtype population is limited.

The heavy dominance of adenocarcinoma means most clinical guidelines, reimbursement rules, and companion testing logic still center on that disease form across the prostate cancer diagnostics market. Rare subtypes therefore matter less because of present volume and more because they expose the limits of conventional diagnostic frameworks. Companies that can address these gaps may gain high-value specialist demand even without a mass screening scale. This also means the prostate cancer diagnostics industry is likely to stay uneven, with broad-volume products built around adenocarcinoma and higher-complexity platforms aimed at diagnostically difficult minority populations. Over time, rare-subtype work can influence platform design more than it changes near-term revenue mix.

By Stage: Castration-Resistant Prostate Cancer Commands Investment Intensity

Localized prostate cancer held 53.62% share in 2025, while castration-resistant prostate cancer is projected to grow at an 10.98% CAGR through 2031. Localized disease remains the largest stage segment because organized screening and earlier workup generate the highest patient volumes at this point in the care pathway. Castration-resistant disease grows faster because each patient usually needs more intensive testing, more molecular selection, and closer monitoring than patients with earlier-stage disease. The prostate cancer diagnostics market, therefore, sees very different economics by stage, with localized disease driving volume and advanced disease driving testing complexity. In metastatic castration-resistant settings, biomarker selection for targeted therapies pushes genomic profiling and ctDNA tools from optional use toward treatment-linked necessity.

This split shapes product strategy across the prostate cancer diagnostics market. Vendors focused on localized disease benefit from scale, screening linkages, and efficient referral integration. Vendors focused on later-stage disease benefit from higher clinical intensity, stronger treatment dependence, and repeat-testing opportunities. Recurrent and advanced patients with rising PSA after primary therapy also support the move toward longitudinal molecular monitoring when conventional imaging is less sensitive. That is why stage mix matters not only for test volumes, but also for pricing resilience and clinical stickiness across the prostate cancer diagnostics market.

By End User: Reference Laboratories Scale to Meet Genomic Complexity

Hospital urology departments held 49.19% share in 2025, while oncology reference laboratories are projected to grow at an 8.57% CAGR through 2031. Hospitals remain the largest end-user base because biopsy, histopathology, mpMRI triage, and initial specialist workup are still centered there. Reference laboratories are growing faster because complex genomic assays and ctDNA workflows need centralized bioinformatics, high-throughput processing, and accreditation capabilities that most hospital labs do not maintain at a comparable scale. This pushes a larger share of advanced testing out of local facilities and into specialized networks. Quest Diagnostics and Labcorp are positioned to benefit from this shift because they already operate large physician-ordering and molecular-testing infrastructures.

Urology clinics are still extending their role within the prostate cancer diagnostics market, especially where office-based biopsy pathways are becoming more practical. A 2025 Scientific Reports study found that freehand transperineal prostate biopsy under local anesthesia achieved a 47.4% clinically significant cancer detection rate without infectious complications, which supports broader outpatient use. Diagnostic imaging centers also gain importance as advanced imaging becomes more integrated into staging and treatment planning. Research and academic institutes remain smaller in routine clinical volume, but they continue to influence assay development, validation design, and future workflow standards across the prostate cancer diagnostics market.

Geography Analysis

North America accounted for 43.64% of the prostate cancer diagnostics market share in 2025, which made it the leading regional contributor by value. The region benefits from high PSA testing penetration, strong specialist infrastructure, and a reimbursement environment that is gradually expanding support for genomic classifiers and advanced imaging. The United States alone is expected to record 333,830 new prostate cancer cases in 2026, which sustains a very large testing base across screening, staging, and follow-up. CMS coverage for selected genomic tools and strong uptake of PSMA PET in higher-risk patients strengthen North America’s leadership in the prostate cancer diagnostics market. Canada benefits from coordinated provincial cancer programs but still shows less advanced imaging depth outside major academic centers, while Mexico remains more PSA-centric with advanced imaging concentrated in private networks.

Europe remains clinically sophisticated, but the prostate cancer diagnostics market is more uneven there because screening policy, reimbursement depth, and implementation speed vary widely by country. Germany’s high-risk staging pathways and the wider EU regulatory environment favor established vendors with validated assay portfolios. The United Kingdom’s MRI-first approach before prostate biopsy has become a recognized model for limiting unnecessary procedures while preserving diagnostic quality. Sweden is also building evidence through region-based organized prostate cancer testing programs with standardized risk-stratified protocols. France, Spain, and Italy are expanding structured PSA access, and Lombardy’s pilot results show that large urban screening models can scale without obvious overdiagnosis in early implementation.

Asia-Pacific is the fastest-growing region, and the prostate cancer diagnostics market size there is projected to rise at a 9.96% CAGR through 2031 as screening and diagnostic infrastructure catch up with disease burden. More than 60% of prostate cancer patients in China are diagnosed at advanced stages, while the United States diagnoses around 70% at localized or regional stages, which highlights the scale of under-screening and under-staging in the region. Japan’s 2025 guideline shift toward individual PSA screening and Chinese evidence supporting the Prostate Health Index both support stronger test adoption in the region. India, South Korea, and Australia add further growth potential, while the Middle East and Africa and South America continue to expand from smaller bases with uptake led by private networks, targeted partnerships, and selective investment in advanced imaging and molecular testing.